Altimmune, Inc.

ALT

$3.28

+6.15%

2026-09-02 16:00:01 EDT+$0.19

Healthcare

Biotechnology

NASDAQ

Active Trading

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide ...

Price Action of ALT

$3.28

+6.15%+$0.19

High—

Low—

52W High-49.1%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, founded in 1997. The company focuses on developing next-generation peptide-based therapeutics for serious metabolic and liver diseases. Its lead investigational drug, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist currently in Phase 1b clinical trials for obesity and ...Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, founded in 1997. The company focuses on developing next-generation peptide-based therapeutics for serious metabolic and liver diseases. Its lead investigational drug, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist currently in Phase 1b clinical trials for obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate for chronic hepatitis B, in Phase 2 trials. The company was originally named Vaxin Inc. and adopted the Altimmune name in September 2015. With 57 full-time employees, Altimmune operates as a lean organization. Financially, the company has a market cap of approximately $267 million, with significant cash reserves (cash per share of $2.66) and no dividend. However, it is pre-revenue, leading to substantial net losses and negative operating cash flow, reflected in its price-to-sales and profitability ratios. The company is led by CEO Jerome Durso, who succeeded Vipin Garg. Key executives include CFO Christophe Arbet-Engels and Chief Medical Officer Scot Roberts. The company's pipeline holds promise, and its cash position (current ratio of 29.6) suggests it can fund operations into the near term. However, the high burn rate and reliance on clinical trial outcomes introduce significant risk. Altimmune aims to address unmet needs in obesity and liver diseases, with potential for significant returns if its candidates succeed in trials.ExpandCollapse

Founded

1997

Employees

CEO

Jerome Benedict Durso

Full Name

Altimmune, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-31.41%

Market Cap

$0.64B

Current Ratio

26.78

WACC

5.36%

ROIC

-28.76%

Contact Information

https://altimmune.com

240 654 1450

910 Clopper Road, Gaithersburg, MD 20878

Key Metrics of ALT

Snapshot

Latest / TTM · 6 periods

Market Cap

$637.87M

ROCE

-19.5%

EV / EBITDA

-6.49x

+16.2% YoY

FCF Yield

-12.2%

+9.0% YoY

Cash Conversion Cycle

39306.6d

Current Ratio

26.78

Quick take

TTM —

Positive CCC

Financial Highlights of ALT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-48306.5%

Net Margin

-296000.0%

P/E Ratio

-4.14x

n/a

Debt / Equity

0.08

n/a

Current Ratio

26.78

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ALT

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.14 · Revenue $1750.00 · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.16 · Revenue $1750.00 · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.59 · Revenue $1875.00 · 6 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.17 · Revenue $18.49M · 3 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.12 · Revenue $0.00
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.18 · Revenue $0.00
View filing
Mar 6, 2026
FY2025 · Annual results
EPS $-1.00 · Revenue $41000.00
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.21 · Revenue $5000.00
View filing
Aug 12, 2025
Q2 FY2025 · Results reported
EPS $-0.27 · Revenue $5000.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.26 · Revenue $5000.00
View filing

Financial Statements of ALT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$41000	+105.0%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-88.1M	+7.3%	-1.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+100.0%	0.0%	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-230461.0%	+55.3%	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-214861.0%	+54.8%	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-67.5M	+15.4%	-15.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-164746.3%	+58.7%	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	15.9%	+1065.9%	-40.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	18.55x	+41.5%	-9.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$279.9M	+100.9%	+57.1%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.00 vs -0.98	-2.4%	-0.12 vs -0.14	+11.2%
Revenue Surprise	$41000 vs $5556	+637.9%	$0 vs $1750	-100.0%

Insider Transactions of ALT

Acquisitions (A)

Since May 1, 2026

Disposals (D)

Since May 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 13, 2026	Durso Jerome Benedict	director, officer: President and CEO	Common Stock, par value $0.0001	A	15,000	$2.95
Jul 31, 2026	WEAVER GREGORY L	officer: Chief Financial Officer	Common Stock, par value $0.0001	A	1,753	$2.41
Jul 31, 2026	Roberts M Scot	officer: Chief Scientific Officer	Common Stock, par value $0.0001	A	875	$2.41
May 1, 2026	Lawver Teri L	director	Stock Options (option to buy)	A	48,800	$2.82
May 1, 2026	Sohn Catherine A.	director	Stock Options (option to buy)	A	48,800	$2.82

Earnings Call Transcript of ALT

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning, ladies and gentlemen. Welcome to the Altimmune Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I'm going to introduce your host for today's conference call, Luis Sanay, Vice President of Investor Relations. Luis, you may begin. Luis Sanay: Thank you, operator, and good morning, everyone. Thank you for joining us for Altimmune's second quarter 2026 financial results and business update call. On today's call, you will hear from Jerry Durso, our Chairman and Chief Executive Officer; Dr. Christophe Arbet-Engels, Chief Medical Officer; Linda Richardson, Chief Commercial Officer; and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we'll open the line for questions. Our second quarter 2026 earnings release was issued this morning and can be found in the Investor Relations section of our website. Before we begin, I would like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for the purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a review of the risk factors that could affect the company's future results and operations, we refer you to our SEC filings. I also direct you to read the forward-looking statements disclaimer in our press release issued this morning. Any statements made on this call speak only as of today's date, August 12, 2026, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this call is being recorded and will be available for audio replay on our website. With that, I'll now turn the call over to Jerry. Jerome Durso: Good morning, everyone. Thank you for joining us today for our second quarter 2026 financial results and business update call. 2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases. We've been laser-focused on execution since the beginning of the year and believe we're well-positioned to advance our strategy and deliver on our mission. Pemvidutide is our foundation, and our confidence and conviction in its potential continues to strengthen with the growing body of clinical evidence. We're building momentum across our pemvidutide franchise and are excited for the future. Let me take a minute to highlight our recent progress. Starting with MASH, last week we announced the initiation of the PERFORMA Phase III trial as we began enrolling patients in the global program. We worked with urgency to get the trial started quickly, just 3 months after securing the financial resources to fund the study …

Leadership Team of ALT

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Scot Roberts	Chief Scientific Officer	USD 683,229	—	1959	Active
Gregory L. Weaver	Chief Financial Officer	USD 619,694	Male	1956	Active
Raymond Jordt	Chief Business Officer	USD 578,850	Male	1973	Active
Christophe Arbet-Engels	Chief Medical Officer	USD 361,356	—	1963	Active
Jerome Benedict Durso	Chairman, CEO & President	USD 50,941	Male	1968	Active
Tony Blandin	Vice President of Quality & Compliance Management	—	Male	—	Active
Andrew Shutterly	Principal Financial & Accounting Officer and Corporate Controller	—	Male	1988	Active
Bertrand Georges	Chief Technology Officer	—	Male	—	Active
Robin E. Abrams	Chief Legal Officer & Corporate Secretary	—	Female	1964	Active
Linda Richardson	Chief Commercial Officer	—	Female	1964	Active

Recent News of ALT

Zacks Investment Research8/19/2026Neutral

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Zacks Investment Research8/19/2026Neutral

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Zacks Investment Research8/13/2026Neutral

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Defense World8/13/2026Neutral

Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,045,926 shares of the company's stock after purchasing an additional 762,223 shares during the quarter. Dimensional Fund Advisors

Seeking Alpha8/12/2026Neutral

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Historical Employee Count of ALT

Current

Change

-3.39%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	57	10-K	Mar 6, 2026	View
Dec 31, 2024	59	10-K	Feb 27, 2025	View
Dec 31, 2023	59	10-K	Mar 27, 2024	View
Dec 31, 2022	52	10-K	Feb 28, 2023	View
Dec 31, 2021	47	10-K	Mar 15, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Altimmune, Inc.